Kyowa Kirin Co Ltd

Kyowa Kirin Co., Ltd. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of medicines, with a primary focus on therapeutic areas including oncology, nephrology, central nervous system disorders, and immunological conditions. The company's extensive pharmaceutical portfolio encompasses solutions across its core therapeutic areas. Within oncology, key products include ABSTRAL, a sublingual fentanyl formulation for breakthrough cancer pain management, and LEUNASE, utilized for acute lymphoblastic leukemia. They also offer GRAN, a human colony-stimulating factor, and the G-LASTA/Peglasta/Neulasta range, developed to address chemotherapy-induced febrile neutropenia. Pain management also includes PecFent, a nasal spray, while SANCUSO is available to treat chemotherapy-related nausea and vomiting. POTELIGEO, a humanized monoclonal antibody, targets the CC chemokine receptor 4. In nephrology, Kyowa Kirin's offerings feature CONIEL, a calcium channel blocker for hypertension and angina pectoris, along with erythropoiesis stimulating agents like ESPO and NESP. Treatments for secondary hyperparathyroidism include REGPARA and the oral calcimimetics agent ORKEDIA. Crysvita, a recombinant human monoclonal IgG1 antibody, is specifically designed to target fibroblast growth factor 23. For central nervous system disorders, Nouriast/Nourianz acts as an adenosine receptor antagonist in Parkinson's disease. Immunological conditions and allergies are addressed by ALLELOCK, an antihistamine, and LUMICEF, a biological therapy for moderate to severe plaque psoriasis. Additional products include Moventig, a mu-opioid receptor antagonist for opioid-induced constipation, and Romiplate/Nplate, a genetically recombinant protein that stimulates platelet production via thrombopoietin receptors. Beyond its existing portfolio, Kyowa Kirin is actively expanding its pipeline through strategic collaborations. A notable partnership with Amgen Inc. involves the co-development and future commercialization of KHK4083. This Phase 3-ready asset is an anti-OX40 fully human monoclonal antibody intended for the treatment of atopic dermatitis. Tracing its origins back to its incorporation in 1949, the company adopted its current name, Kyowa Kirin Co., Ltd., in June 2019, previously operating as Kyowa Hakko Kirin Co., Ltd. It maintains its headquarters in Tokyo, Japan, and operates as a subsidiary of Kirin Holdings Company, Limited.